52234

🔬 CPT 52234 — Cystourethroscopy, With Fulguration And/Or Resection Of; Small Bladder Tumor(s) (0.5 Up To 2.0 cm)

Quick Reference

wRVU: 3.77 | Global Period: 000 (same day) | Assistant Payable: ❌ No | Bilateral Indicator: 0

---

📋 Clinical Description

CPT 52234 describes a cystourethroscopy performed with transurethral fulguration and/or resection of one or more small bladder tumors measuring 0.5 cm up to 2.0 cm. A rigid or flexible cystoscope is passed transurethrally into the bladder under direct visualization; identified tumors are destroyed or resected using electrocautery (monopolar or bipolar), cryosurgery, or laser energy (Nd:YAG, holmium, green light). The procedure includes the diagnostic endoscopic survey of the entire bladder and urethra as a bundled component. Code selection within the tumor-resection family (52224, 52234, 52235, 52240) is driven entirely by tumor size — not the number of tumors, not the technique used, and not how many sites are treated.

C67.x bladder tumors are the most common indication, with non-invasive papillary urothelial carcinoma (Ta) representing the majority of cases treated transurethrally. Transurethral resection of bladder tumor (TURBT) serves a dual purpose: it is simultaneously diagnostic (providing tissue for pathologic staging and grading) and therapeutic (achieving local tumor control). The critical size distinction for code selection is the size of the largest individual tumor for Medicare; many commercial payers permit aggregation of all tumor sizes when multiple tumors are treated in the same session — a difference that significantly impacts code selection and must be understood before claim submission.

This procedure may be performed in the following clinical contexts:

• Primary TURBT for newly diagnosed bladder tumor — Visible bladder lesion identified on CT urography, cystoscopy, or workup for hematuria; TURBT provides both definitive staging and initial tumor control for Ta/T1 urothelial carcinoma.
• Surveillance TURBT in a patient with history of bladder cancer — Recurrent low-grade non-invasive papillary urothelial carcinoma (Z85.51 as secondary; current malignancy C67.x or D41.4 as PDx) discovered on scheduled surveillance cystoscopy; the most common indication for repeat 52234 billing.
• Fulguration of carcinoma in situ (CIS) or flat lesion — CIS (Tis) mapped to C67.x may be treated with electrofulguration without resection; the “and/or” language in the descriptor covers fulguration-only encounters when resection is not performed.
• Re-TURBT for residual or inadequately staged disease — Second-look TURBT within weeks of an initial resection to verify complete resection or re-stage; C67.x remains the driving diagnosis; document the restaging intent clearly in the operative note to distinguish from a routine surveillance case.
• TURBT of incidentally found small lesion during procedure for another indication — Incidental papillary lesion encountered during cystoscopy performed for an unrelated reason (e.g., ureteral stone management); document lesion size and treatment modality to support 52234 alongside the primary procedure code with modifier -59.

---

🔬 Anatomical & Procedural Considerations

Technique / Modality	Mechanism	Key Notes
Electrocautery — Monopolar TURBT Loop	Electrical current via a resecting loop removes tumor en bloc or in fragments; tissue sent for pathology	Most common technique; provides specimen for histologic analysis; requires non-conductive irrigant (glycine or sterile water) to prevent current dispersion
Electrocautery — Bipolar (TURis)	Current flows between two electrodes at the resecting element; allows use of normal saline irrigation	Reduced risk of TUR syndrome; preferred when anticoagulation is a concern or for patients with cardiac pacemakers
Fulguration (Electrosurgical Coagulation Without Resection)	High-frequency current destroys superficial lesion tissue in situ without recovering specimen	Appropriate only for very superficial lesions when tissue is not needed for staging; insufficient for primary staging of new lesions — document medical necessity; no specimen means no pathologic confirmation
Laser (Nd:YAG / Holmium / Green Light)	Focused laser energy ablates or vaporizes tumor; holmium allows en bloc resection	”Including cryosurgery or laser surgery” language is explicit in the CPT descriptor — technique does not change code selection; operative note must document the specific laser type used
Cryosurgery	Extreme cold destroys tumor cells via freeze-thaw cycles	Least common modality in current U.S. practice; included in descriptor; no separate code or modifier required to identify cryosurgery technique

Clinical Pearl

The single most audited documentation element for CPT 52234 is tumor size as measured or estimated at the time of cystoscopy. The operative note must state a specific size in centimeters — not descriptors like “small,” “pea-sized,” or “pinpoint.” Medicare bases code selection on the largest single tumor removed in one session; without a documented size, the claim defaults to 52224 (minor, <0.5 cm) on audit. If the operative report documents “1.0 cm lesion resected,” that unambiguously supports 52234. If size is absent, query the urologist before submission — never estimate size yourself.

---

✅ Procedure Includes

• Transurethral insertion and advancement of rigid or flexible cystoscope through the urethra into the bladder
• Complete endoscopic survey of the entire urethra, bladder, and ureteral orifices
• Irrigation and visualization of all bladder walls, dome, trigone, and lateral walls
• Fulguration and/or resection of small bladder tumor(s) (0.5 cm up to 2.0 cm) using any modality
• Hemostasis of the resection site
• Collection and submission of resected tissue for pathologic analysis (when tissue is obtained)
• Catheter placement and removal as clinically indicated
• Documentation of tumor size, location, number, and appearance in the operative note

---

❌ Excludes / Do Not Report Together

Code	Description	Relationship to 52234
52000	Cystourethroscopy, diagnostic (separate procedure)	Bundled — diagnostic cystoscopy is integral to 52234 and is not separately reportable in the same session; the endoscopic survey is included in the more comprehensive therapeutic code
52224	Cystourethroscopy, with fulguration or treatment of minor lesion(s) (<0.5 cm)	Mutually exclusive within same session for same lesion — select the code matching the largest tumor treated; 52224 and 52234 report the same session’s work at different size thresholds; do NOT report both for the same operative encounter unless distinct lesions of different sizes are documented and modifier -59 is applied
52235	Cystourethroscopy, fulguration/resection of medium bladder tumor(s) (2.0-5.0 cm)	Bundled — 52235 subsumes 52234 when a medium tumor is also treated in the same session; report only the code for the largest tumor (Medicare) or aggregate size (many commercial payers); cannot report 52234 and 52235 together for the same session without modifier -59 for distinctly different tumor sites
52240	Cystourethroscopy, fulguration/resection of large bladder tumor(s) (>5.0 cm)	Bundled — 52240 subsumes all smaller tumor codes when a large tumor is present in the same session for Medicare; 52234 cannot be separately reported alongside 52240 without modifier -59 documenting a distinct and separate tumor site
52204	Cystourethroscopy with biopsy	Bundled — when a biopsy and resection of the same lesion are performed, bill only the resection code (52234); do NOT report 52204 alongside 52234 for the same lesion; may be separately reported with modifier -59 only if a biopsy is taken from a different, distinct lesion that is not fulgurated or resected
E/M codes (992xx)	Office visit, any level	Separately reportable only when modifier -25 is appended to the E/M code, documenting a significant, separately identifiable E/M service beyond the routine pre-procedure assessment on the same date; the decision to perform the minor endoscopic procedure is included in the procedure payment

Bundling Alert — Global Period is 000, Not 010 or 090

CPT 52234 has a 000-day global period (same-day only). This means the global package applies only on the date of the procedure itself — pre-procedure evaluation on the same date is bundled, but any follow-up on subsequent days is not included in the global package and may be billed separately without a modifier. The most common compliance error is applying 90-day global logic (modifier -78 for return to OR, modifier -79 for unrelated procedure) when in fact no global restriction exists beyond the procedure date. However: if a patient returns to the OR on the same date for a complication, the global concept does apply. For any subsequent date, no modifier is required to separately bill a follow-up visit or a new procedure.

---

🌳 Code Tree — Surgery: Urinary System — Transurethral Procedures

52000-52700  Surgery: Urinary System — Endoscopy / Transurethral Procedures
│
├── 52000       Cystourethroscopy (diagnostic, separate procedure)
│
├── 52204-52240  Cystourethroscopy with Biopsy, Fulguration, and/or Resection
│   ├── 52204   Cystourethroscopy, with biopsy(s)  (Global: 000)
│   ├── 52214   Cystourethroscopy, with fulguration of trigone, bladder neck, prostatic fossa, urethra  (Global: 000)
│   ├── 52224   Cystourethroscopy, fulguration/treatment of MINOR lesion(s) (<0.5 cm) ± biopsy  (Global: 000)
│   ├── ▶▶ 52234 ◀◀  Cystourethroscopy, fulguration and/or resection of SMALL tumor(s) (0.5-2.0 cm)  ← YOU ARE HERE  (Global: 000)
│   ├── 52235   Cystourethroscopy, fulguration/resection of MEDIUM tumor(s) (2.0-5.0 cm)  (Global: 000)
│   └── 52240   Cystourethroscopy, fulguration/resection of LARGE tumor(s) (>5.0 cm)  (Global: 000)
│
├── 52250       Cystourethroscopy with insertion of radioactive substance
├── 52260-52265 Cystourethroscopy with dilation and hydrodistension
└── 52270-52285 Cystourethroscopy with urethral procedures

---

💰 RVU & Reimbursement Profile

Component	Value
Work RVU (wRVU)	3.77 (verify against current CMS MPFS for applicable year)
Global Period	000 (same day)
Bilateral Indicator	0 — Not applicable; bladder is an unpaired midline structure; bilateral payment rules do not apply
Assistant Surgeon	❌ Not payable under Medicare for 52234
Co-Surgeon	❌ Not applicable
Team Surgery	❌ Not applicable
PC/TC Split	❌ No — procedure code only (Indicator 0)
Modifier -51 Exempt	No
Anesthesia	General or spinal anesthesia typical for hospital/ASC cases; local or topical anesthesia may be used for office-based flexible cystoscopy; anesthesia separately billable under appropriate anesthesia CPT

Medicare vs. Commercial Payer Tumor Size Rules

CPT 52234 is the code where Medicare and commercial payer rules diverge most sharply in urology. Medicare: Bill based on the size of the largest single tumor removed in the session. If three tumors are removed measuring 0.5 cm, 1.0 cm, and 1.5 cm, bill 52234 once — the largest individual tumor is 1.5 cm, which falls within the small range. Many commercial payers (varies by contract): Aggregate all tumor sizes together and bill the code matching the total. The same three tumors (0.5 + 1.0 + 1.5 = 3.0 cm aggregate) would support 52235 (medium) under an aggregation policy. Always verify each payer’s specific policy before submission — this distinction is a direct source of undercoding (if Medicare rules applied to commercial) or overcoding risk (if commercial rules are applied to Medicare). Document tumor count and individual sizes in the operative note regardless of payer.

---

🏷️ Modifier Reference

Modifier	Name	When to Apply
-25	Significant, Separately Identifiable E/M	Applied to the E/M code — not 52234 — when an office visit is performed on the same date; documentation must support a separate, medically necessary evaluation beyond the pre-procedure assessment; the 000-day global period means only same-day E/M is affected
-51	Multiple Procedures	When 52234 is reported alongside other surgical procedures in the same session (e.g., ureteral stent placement 52332, ureteroscopy); apply -51 to the lower-valued code
-52	Reduced Services	Procedure partially completed — document reason (e.g., patient intolerance, equipment failure); rare for this endoscopic procedure
-53	Discontinued Procedure	Procedure stopped due to patient safety concern before fulguration/resection is accomplished; document thoroughly
-58	Staged or Related Procedure	Planned re-TURBT during a follow-up session that was anticipated and documented at the time of initial resection (e.g., planned re-TURBT for T1 high-grade disease)
-59	Distinct Procedural Service	When 52234 is reported alongside 52235 or 52240 for distinctly different tumor sites in the same bladder in the same session; documents a genuinely separate lesion at a different anatomic location; requires explicit documentation of each lesion’s size and location in the operative note
-22	Increased Procedural Services	Use with caution and only when complexity markedly exceeds the standard — e.g., extremely tortuous urethra, prior radiation changes, unusual bleeding, or multifocal disease requiring significantly extended operative time; do NOT use simply to indicate multiple tumors, as the code descriptor already accounts for “tumor(s)” (plural)
-76	Repeat Procedure by Same Physician	Repeat TURBT by the same physician on the same date due to immediately recurring clinical indication
-79	Unrelated Procedure During Postoperative Period	Not applicable — 000-day global period means there is no ongoing global window after the procedure date; no modifier required for services on subsequent days

---

🩺 Common ICD-10-CM Pairings

Primary Bladder Malignancy

ICD-10 Code	Description	HCC?	Clinical Notes
C67.1	Malignant neoplasm of dome of bladder	✅ HCC 11	Document tumor site in cystoscopy report; dome lesions are visible at the top of the bladder; surgeon’s note should specify location relative to the ureteral orifices
C67.2	Malignant neoplasm of lateral wall of bladder	✅ HCC 11	Most common location for papillary urothelial carcinoma; left vs. right lateral wall should be documented but ICD-10-CM C67.2 does not distinguish laterality
C67.4	Malignant neoplasm of posterior wall of bladder	✅ HCC 11	Posterior wall tumors are common recurrence sites; document clearly for surveillance cases
C67.5	Malignant neoplasm of bladder neck	✅ HCC 11	Bladder neck tumors may require additional documentation regarding ureteral orifice proximity and resection margins
C67.9	Malignant neoplasm of bladder, unspecified	✅ HCC 11	Use only when anatomic site within the bladder is truly absent from all documentation; query provider for site specificity before defaulting to unspecified

Neoplasm of Uncertain or Unspecified Behavior (Pre-Pathology / Surveillance)

ICD-10 Code	Description	HCC?	Clinical Notes
D41.4	Neoplasm of uncertain behavior of bladder	❌ No	Use when pathology result identifies the lesion as borderline or transitional — e.g., papilloma with atypia; also appropriate pre-operatively when a lesion is identified on imaging and malignancy is suspected but not yet confirmed by pathology
D49.4	Neoplasm of unspecified behavior of bladder	❌ No	Appropriate when the operative note documents a “bladder lesion” or “papillary lesion” and pathology is pending at time of coding; update to more specific code once pathology is finalized per payer policy

Presenting Symptoms and Surveillance Diagnoses

ICD-10 Code	Description	HCC?	Clinical Notes
R31.0	Gross hematuria	❌ No	Appropriate as PDx when TURBT is performed in the setting of hematuria and malignancy is suspected but not yet confirmed; update upon pathology return
R31.1	Benign essential microscopic hematuria	❌ No	Use when microscopic hematuria prompted the diagnostic workup that revealed the lesion
Z85.51	Personal history of malignant neoplasm of bladder	❌ No	Use as secondary diagnosis for surveillance TURBT cases; pair with C67.x (if current malignancy found) or D41.4/D49.4 as PDx when lesion behavior is not yet pathologically confirmed at time of the surveillance procedure

Underlying Etiology / Complication Codes

ICD-10 Code	Description	HCC?	Clinical Notes
T65.3XXA	Toxic effect of nitriles, accidental; initial encounter	❌ No	When occupational/chemical exposure is a documented contributing etiology for bladder cancer; append as secondary
F17.210	Nicotine dependence, cigarettes, uncomplicated	❌ No	Tobacco use is the single strongest risk factor for urothelial carcinoma; code and document when present — supports medical necessity narrative and captures risk factor for quality reporting

Coding Specificity Reminder

The most common specificity gap for 52234 pairings is the pre-pathology vs. post-pathology diagnosis question. At the time of TURBT, the final histologic diagnosis is unknown — the coder must assign the most accurate code available based on what the surgeon documents. If the operative note says “bladder tumor, papillary appearance” with no pathology back yet, D49.4 or D41.4 is appropriate. Once pathology returns confirming malignancy, update to C67.x with the appropriate anatomic site. Some payers require the diagnosis code at time of claim submission to reflect final pathology; confirm payer-specific policy for this code family. ICD-10-CM specificity requirements are not optional — do not default to C67.9 (unspecified site) without first checking that the site is truly absent from the cystoscopy report, operative note, and pathology report.

---

🏥 MS-DRG Considerations (Inpatient)

Inpatient Coding Reminder

CPT 52234 is performed primarily in the outpatient and ASC setting. Inpatient admission for TURBT of a small bladder tumor alone is not clinically expected and would not be supported by payer utilization review without documented comorbidities or staging complexity. When a patient is admitted as an inpatient and undergoes TURBT during that stay — whether as the primary procedure or as an incidental finding treated during another admission — the ICD-10-PCS codes below are assigned on the facility claim rather than CPT codes. The PCS procedure codes for TURBT (excision or destruction of bladder) group under MDC 11 (Diseases and Disorders of the Kidney and Urinary Tract):

• DRG 673 — Other Kidney and Urinary Tract Procedures with MCC
• DRG 674 — Other Kidney and Urinary Tract Procedures with CC
• DRG 675 — Other Kidney and Urinary Tract Procedures without CC/MCC

CC/MCC accuracy matters even for this lower-acuity procedure when it occurs during an inpatient stay. If the patient has documented bladder cancer with concurrent sepsis, acute blood loss anemia (D62), or malnutrition, code all confirmed comorbidities to maximize DRG tiering.

---

🔧 ICD-10-PCS Equivalents (Inpatient Facility Coding)

Note

TURBT with resection of bladder tumor maps to two possible root operations in ICD-10-PCS depending on what was physically done. Excision (B) is used when tumor tissue is cut out and sent for pathology — this is the standard TURBT with resection. Destruction (5) is used when the lesion is destroyed in place without tissue recovery (pure fulguration, laser ablation without specimen). The approach for both is Via Natural or Artificial Opening Endoscopic (8) — the transurethral cystoscopic approach. A single operative session that includes both resection AND fulguration may require both PCS codes.

PCS Code	Full Description	Applicable Technique
0TBB8ZX	Excision of Bladder, Via Natural or Artificial Opening Endoscopic, Diagnostic	TURBT with resection where specimen is sent for pathologic analysis (diagnostic qualifier X)
0TBB8ZZ	Excision of Bladder, Via Natural or Artificial Opening Endoscopic	TURBT with resection — therapeutic (qualifier Z, No Qualifier); use when tissue is sent to pathology but intent is clearly therapeutic
0T5B8ZZ	Destruction of Bladder, Via Natural or Artificial Opening Endoscopic	Fulguration only — when tumor is destroyed in place without tissue recovery; electrocautery or laser ablation of CIS or superficial lesion

PCS Character Analysis — 0TBB8ZX

Position	Character	Value	Definition
1	Section	0	Medical and Surgical
2	Body System	T	Urinary System
3	Root Operation	B	Excision (cutting out or off, without replacement, a portion of a body part)
4	Body Part	B	Bladder
5	Approach	8	Via Natural or Artificial Opening Endoscopic
6	Device	Z	No Device
7	Qualifier	X	Diagnostic (tissue sent for pathologic analysis)

PCS Root Operation: Excision (B) vs. Destruction (5)

• Use Excision (B) when the operative note documents that tumor tissue was cut, resected, or removed and sent to pathology — this is the standard TURBT scenario and captures the diagnostic value of the procedure.
• Use Destruction (5) when the operative note documents pure fulguration, laser ablation, or cryoablation of a lesion without tissue recovery — the lesion is destroyed in situ and no specimen is submitted.
• When both resection and fulguration are performed on separate lesions in the same session, assign both 0TBB8ZX (or 0TBB8ZZ) and 0T5B8ZZ, as they represent distinct root operations applied to different lesions.
• The Diagnostic qualifier (X) is used on the Excision code when the primary purpose of removing tissue includes obtaining a diagnostic specimen. When the resection is clearly therapeutic (complete removal of a known tumor), the No Qualifier (Z) is used.

---

📝 Coding Examples

---

Example 1 — Outpatient Hospital / ASC: Surveillance TURBT, Single Small Tumor, Known History

Clinical Scenario: A 71-year-old male with a history of low-grade non-invasive papillary urothelial carcinoma of the right lateral bladder wall presents for routine 3-month surveillance cystoscopy. The urologist identifies a single recurrent papillary lesion measuring 1.2 cm on the posterior wall, which is resected transurethrally using a monopolar resecting loop. Specimen is submitted to pathology. The operative report documents: “Single papillary lesion, posterior wall, estimated 1.2 cm; transurethral resection performed; specimen sent to pathology.” No separate E/M visit is documented on the same date.

Field	Code	Rationale
CPT	52234	TURBT, small tumor (1.2 cm falls within 0.5-2.0 cm range); no modifier required — single surgeon, single payer, no co-procedure
PDx	C67.4	Malignant neoplasm of posterior wall of bladder — the recurrent tumor site is documented; most specific available code
SDx	Z85.51	Personal history of malignant neoplasm of bladder — supports the surveillance context and prior disease history

Note

Modifier -25 is not indicated here because no separate E/M service was documented. If the urologist had performed a pre-procedure evaluation on the same date with documentation of a separately identifiable clinical decision-making service beyond the immediate pre-procedure assessment, modifier -25 would be appended to the E/M code only — not to 52234.

---

Example 2 — Outpatient Hospital: Multiple Small Tumors, Medicare vs. Commercial Payer Coding Decision

Clinical Scenario: A 65-year-old female with recurrent low-grade urothelial carcinoma presents for surveillance TURBT. Cystoscopy reveals three separate papillary lesions: one measuring 0.8 cm on the dome, one measuring 1.4 cm on the right lateral wall, and one measuring 1.6 cm on the posterior wall. All three are resected in the same operative session using bipolar electrocautery. Specimens are submitted separately by site. The patient’s insurance is Medicare.

Field	Code	Rationale
CPT	52234	Medicare rule: bill based on the largest single tumor — 1.6 cm is the largest, which falls within the small range (0.5-2.0 cm); only one code is reported; do NOT report three units of 52234
PDx	C67.4	Malignant neoplasm of posterior wall of bladder — posterior wall lesion is the largest and most specific documented site; code the dominant/driving lesion
SDx	C67.1	Malignant neoplasm of dome of bladder — second tumor site, separately documented
SDx	C67.2	Malignant neoplasm of lateral wall of bladder — third tumor site

Warning

For a commercial payer following an aggregation policy, these same three tumors (0.8 + 1.4 + 1.6 = 3.8 cm aggregate) would support reporting 52235 (medium, 2.0-5.0 cm) instead of 52234. Before upgrading the code for a commercial claim, confirm the payer’s specific policy in the provider contract or fee schedule addendum. Applying commercial aggregation rules to a Medicare claim constitutes overcoding and creates false claims liability.

---

Example 3 — Outpatient Hospital: TURBT Plus Ureteral Stent, Modifier -59 Application

Clinical Scenario: A 68-year-old male with bladder cancer presents for TURBT of a known 1.8 cm posterior wall lesion. During the same operative session, the urologist also places a ureteral stent in the right ureter for a separately identified partial ureteral obstruction secondary to extrinsic compression. Both procedures are documented separately in the operative report with distinct indications. A pre-procedure office visit was performed on the same date, with documented history and physical separate from the operative consent discussion.

Field	Code	Rationale
CPT 1	52234	TURBT, small tumor (1.8 cm) — primary procedure
CPT 2	52332-59	Cystourethroscopy with insertion of indwelling ureteral stent — distinct procedural service performed for a separate indication (ureteral obstruction); modifier -59 documents the separate nature; -51 may also apply depending on payer rules for multiple procedures
E/M	99213-25	Office/outpatient visit — modifier -25 on the E/M code; documentation supports a separately identifiable evaluation and management service beyond the pre-procedure assessment
PDx	C67.4	Malignant neoplasm of posterior wall of bladder — drives the TURBT
SDx	N13.5	Crossing vessel and stricture of ureter without hydronephrosis — supports the stent placement

Note

Global period reminder: CPT 52234 has a 000-day global period — the global surgical package applies only on the date of service. Modifier -25 is appropriate on the same-date E/M regardless of whether a different diagnosis is used; the E/M service and the minor surgical procedure do not require different diagnoses under Medicare rules. The 000-day global also means that any follow-up visits on subsequent dates do not require a modifier and may be billed as standard E/M services without restriction.

---

⚠️ Common Coding Pitfalls

• Selecting code by number of tumors rather than size: CPT 52234 and its family members (52224, 52235, 52240) are size-based codes, not count-based. The descriptor “tumor(s)” explicitly uses the plural, confirming that multiple tumors are captured under a single code. Reporting 52234 multiple times or appending modifier -22 simply because multiple tumors were removed is a compliance risk and not supported by CPT guidance. The correct approach is to select the code for the largest single tumor (Medicare) or aggregate size (commercial payers per their specific policy).

• Failing to document tumor size in centimeters in the operative note: The single most common cause of code downgrades on audit is the absence of a specific numeric size in the operative report. Descriptors such as “small,” “pea-sized,” or “minor” do not support 52234 — only an actual measurement in centimeters does. Coders should not assign 52234 without confirming that a size within the 0.5-2.0 cm range is explicitly documented. If size is absent, query the urologist before claim submission.

• Separately billing 52204 (biopsy) alongside 52234 for the same lesion: When a biopsy and resection are performed on the same lesion in the same session, bill only the resection code — 52234 subsumes the biopsy. Separately reporting 52204 for the same lesion creates an NCCI bundling violation. The exception: if a biopsy is taken from a completely different lesion that is not resected or fulgurated, 52204 may be reported with modifier -59 for that distinct lesion.

• Reporting 52000 (diagnostic cystoscopy) with 52234 in the same session: The endoscopic survey of the bladder and urethra is bundled into 52234 per NCCI — 52000 may not be separately reported in the same session by the same provider. This is a direct-column bundling edit with no modifier escape. The diagnostic portion of the procedure is captured in the payment for 52234.

• Applying commercial payer aggregation rules to Medicare claims: Aggregate tumor sizing is a commercial payer-specific policy that does NOT apply to Medicare. Applying aggregation logic to a Medicare claim — e.g., billing 52235 for three small tumors that aggregate to a medium-range total — constitutes upcoding under Medicare and creates false claims exposure. Always confirm the payer before applying the aggregation method, and document the rule source in the coding rationale.

• Missing the distinction between D49.4 / D41.4 and C67.x for pre-pathology vs. post-pathology coding: Assigning a definitive malignancy code (C67.x) when pathology has not yet returned — or when the surgeon’s intraoperative impression does not definitively characterize the lesion as malignant — misrepresents the diagnosis at the time of service. Use D49.4 (unspecified behavior) or D41.4 (uncertain behavior) when pathology is pending or when the lesion’s behavior is not yet confirmed, and update upon receipt of pathology results per payer policy.

---

📎 Sources

¹ AMA CPT 2025 Professional Edition — CPT 52234, Surgery: Urinary System, Urethra and Bladder Transurethral Surgical Procedures · ² CMS 2025 Medicare Physician Fee Schedule Final Rule (CMS-1807-F); CMS RVU25A Relative Value Files — CPT 52234 wRVU 3.77, Global Period 000 · ³ NCCI Policy Manual Chapter 7 (Urinary System), CMS 2025 — bundling edits for 52000, 52204, 52224, 52235, 52240 with 52234 · ⁴ ICD-10-CM Official Guidelines for Coding and Reporting FY2025 — Section I.C.2 (Neoplasm coding; uncertain/unspecified behavior) · ⁵ ICD-10-PCS Official Guidelines for Coding and Reporting FY2025 — Root Operations Excision (B3.4b) and Destruction; Approach Via Natural or Artificial Opening Endoscopic · ⁶ AHA Coding Clinic for HCPCS — TURBT with Removal of 2.0 cm Tumor (2023); clarification of 52234 vs. 52235 boundary at 2.0 cm · ⁷ AAPC CPT Assistant — Coding Brief: Reporting Cystourethroscopy with Fulguration Procedures and Bladder Tumor Resections (2025) · ⁸ AAPC My Urology Coding Alert — “Select Codes for Bladder Tumor Removal by Size, Not Number” — Medicare vs. Commercial aggregation rules · ⁹ CMS ICD-10 MS-DRG v42.1 Definitions Manual — MDC 11, DRG 673/674/675 (Other Kidney and Urinary Tract Procedures with/without CC/MCC) · ¹⁰ Medic Management — “Billing CPT 51720 with Bladder Tumor Resections” (2023) — instillation bundling guidance for same-day 51720 and 52234